Surmeli, H.; Isik, D.; Kinikoglu, O.; Altintas, Y.E.; Ozkerim, U.; Oksuz, S.; Basoglu, T.; Odabas, H.; Turan, N.
Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer. Pharmaceuticals 2025, 18, 931.
https://doi.org/10.3390/ph18060931
AMA Style
Surmeli H, Isik D, Kinikoglu O, Altintas YE, Ozkerim U, Oksuz S, Basoglu T, Odabas H, Turan N.
Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer. Pharmaceuticals. 2025; 18(6):931.
https://doi.org/10.3390/ph18060931
Chicago/Turabian Style
Surmeli, Heves, Deniz Isik, Oguzcan Kinikoglu, Yunus Emre Altintas, Ugur Ozkerim, Sıla Oksuz, Tugba Basoglu, Hatice Odabas, and Nedim Turan.
2025. "Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer" Pharmaceuticals 18, no. 6: 931.
https://doi.org/10.3390/ph18060931
APA Style
Surmeli, H., Isik, D., Kinikoglu, O., Altintas, Y. E., Ozkerim, U., Oksuz, S., Basoglu, T., Odabas, H., & Turan, N.
(2025). Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer. Pharmaceuticals, 18(6), 931.
https://doi.org/10.3390/ph18060931
